The Irvine, California-based company will now market its test to clinical labs throughout the UK for patient testing.

The system consists of a microfluidic cartridge with 640 incubation wells that allows the platform to visually test all clinically relevant antibiotics quantitatively.

The award supports development of a portable test system using the firm's protein nucleic acid probes and semiconductor sensor tech.

The platform analyzes infrared spectroscopy data from a small sample of blood with proprietary algorithms to detect cancer early.

The new funding will help the cluster build on initial milestones and to prepare for clinical applications, particularly in cancer.

Last week, readers were most interested in a story about the conviction of lab owner, formerly an NFL player, for genetic testing fraud.

Among the major issues were tariff policies, reimbursement pathways for multi-cancer early detection tests, and reform of the ...

Life Line aims to offer Lucent's blood-based testing through its mobile delivery model at urban and rural community health screening events.

NEW YORK – Irish diagnostic firm Trinity Biotech announced on Wednesday that it has entered into a $25 million standby equity purchase agreement with an affiliate of its financing partner Yorkville ...

NEW YORK — BioAffinity Technologies said on Wednesday that it will run a study of its CyPath Lung test for early lung cancer detection in collaboration with Brooke Army Medical Center (BAMC). CyPath ...

Moffit Cancer Center researchers found four "protein EpiScores" that were associated with disease-free survival, one of which was also associated with overall survival.

The certification covers assays for pertussis, malaria, chlamydia, gonorrhea, herpes, cytomegalovirus, and group B streptococcus.